论文部分内容阅读
目的探讨心达康对急性心肌梗死 (AMI)静脉溶栓治疗再通及并发症的影响。方法 78例 AMI患者随机分为心达康组 (42例 )与对照组 (3 6例 ) ,两组均以尿激酶常规溶栓治疗 ,心达康组在溶栓治疗同时口服心达康。1个月后比较 2组。再通标准各项指标并发症情况。结果两组再通指标中再灌注性心律失常发生率心达康组为 5 1.72 %明显低于对照组 78.5 7%。有显著性差异 (P<0 .0 5 ) ;胸痛缓解率 88.10 %与 66.67% ,两组有显著性差异 (P<0 .0 5 ) ;心力衰竭发生率 4.76%低于对照组 2 2 .2 2 % (P<0 .0 5 ) ,梗死后心绞痛发生率 7.14 %低于对照组 3 3 .3 3 % (P<0 .0 1)。结论心达康配合尿激酶溶栓治疗 AMI,可提高疗效 ,减少再灌注心律失常等并发症 ,降低病死率。
Objective To investigate the effect of Xinkakang on recanalization and complications of intravenous thrombolysis in patients with acute myocardial infarction (AMI). Methods 78 patients with acute myocardial infarction (AMI) were randomly divided into Xin Dakang group (42 cases) and control group (36 cases). Both groups were given routine thrombolytic therapy of urokinase. One month later, two groups were compared. Recanalize the standard indicators of complications. Results The incidence of reperfusion arrhythmias in the two groups of recanalization indicators was significantly lower than that of the control group (5 1.72% vs 78.5 7%). There was significant difference (P <0.05); chest pain relief rate was 88.10% and 66.67%, there was a significant difference between the two groups (P <0.05); heart failure rate was 4.76% lower than the control group 2 2. (P <0.05). The incidence of post-infarction angina was 7.14% lower than that of the control group (33.33%, P <0.01). Conclusions Xindakang combined with urokinase thrombolytic therapy for AMI can improve curative effect, reduce complications such as reperfusion arrhythmia and reduce mortality.